Interestingly, the up-regulated expression of SIRT1 and its downstream signaling induced by ATL III in FFAs-treated HepG2 cells was partly blunted, which suggests that AMPK/SIRT1 signaling pathway is the crucial mechanism of ATL III ameliorating NAFLD. The gene discussed is SIRT1; the disease is metabolic dysfunction-associated steatotic liver disease.